powder for solution for infusion
Sponsors
University College London, Erasca Inc., Philogen S.p.A., Centre Hospitalier Universitaire De Nice, Unidade Local De Saude De Sao Jose E.P.E.
Conditions
Advanced epithelial ovarianCholangiocarcinomaHeart FailureOsteoarticular infections on equipmentUnresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.Unresectable or metastatic NRAS mutant cutaneous melanomafallopian tube or peritoneal carcinoma stage IA/IIA Hodgkin lymphoma
Phase 2
A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma
Active, not recruitingCTIS2024-512704-20-00
Start: 2020-06-22Target: 98Updated: 2025-10-20
Osteoarticular infections on equipment: impact of three probabilistic antibiotic therapy strategies on the digestive microbiota and gastrointestinal colonization with multidrug-resistant bacteria
Not yet recruitingCTIS2024-513298-29-00
Target: 75Updated: 2025-11-03
Phase 3
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
RecruitingCTIS2022-500031-37-00
Start: 2024-04-08Target: 289Updated: 2025-06-23
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
CompletedCTIS2024-513513-12-00
Start: 2019-01-06End: 2025-06-03Target: 110Updated: 2025-07-23
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
RecruitingCTIS2024-511404-17-00
Start: 2024-10-07Target: 294Updated: 2026-01-07
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Active, not recruitingCTIS2024-519218-30-00
Start: 2021-05-26Target: 64Updated: 2025-12-01